4D Molecular Therapeutics, Inc. FDMT
14.47
(0.24)
(1.63%)
as of 25 Sep
- Market cap
- $807.1M
- P/E
- 0.0×
Follow FDMT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(45.38%) | (27.57%) | (34.92%) | (43.25%) | |
| (40.70%) | (24.86%) | (31.28%) | (37.09%) | ||
ROIC |
(225.26%) | (96.80%) | (184.13%) | (186.91%) | |
Return on Tangible Assets |
(71.78%) | (36.49%) | (42.84%) | (51.54%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 18.29 | |
Free Cash Flow per Share |
(3.30) | (1.89) | (1.90) | (2.22) | |
Free Cash Flow |
(185.05) | (109.62) | (129.34) | (155.96) | |
Capital Expenditures |
(1.55) | (0.54) | 0.11 | 0.11 | |
Piotroski F-Score |
2.00 | 3.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(27.22%) | (12.01%) | (15.36%) | (19.79%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 31.57 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
150,977.50% | 229.67% | 249.29% | 261.18% | |
Selling, General and Administrative Expense of Revenue |
41,105.00% | 57.58% | 54.18% | 53.06% | |
Share Based Compensation of Revenue |
20,034.17% | 25.84% | 22.08% | 22.18% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.78 | 0.80 | 0.87 | |
Depreciation/Fixed assets |
(0.05) | 0.00 | 0.02 | 0.05 | |
Capex/Depreciation |
1.80 | 13.40 | 0.34 | 0.18 | |
Revenue per Share |
0.00 | 1.47 | 1.30 | 1.31 | |
Operating CF per Share |
(3.27) | (1.88) | (1.90) | (2.22) | |
Capex per Share |
(0.03) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
12.96 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(174,314.17%) | (164.43%) | (182.34%) | (194.74%) |
Columns are period end dates